Pages

Monday, June 12, 2017

MedicalConspiracies- New virus

http://www.relayhero.com/farmer-bitten-tick-dying-virus/?utm_source=EGEEK&utm_medium=social&utm_campaign=partnership

--
--
To subscribe: MedicalConspiracies-subscribe@googlegroups.com
Alternative Medicine info: http://www.elementsofhealth.webs.com/

"ClayAdvantage" The Gift of Health http://ClayAdvantage.com/
Holistic Store: http://www.holisticenergystore.com/

Information here in is for educational purpose only; it may be news related,
speculation or opinion. Consult with a qualified MD before deciding on any course of treatment, especially for serious or life-threatening illnesses.
FDA and FTC have not evaluated or endorsed any message or product from this group. http://www.law.cornell.edu/uscode/17/107.shtml

---
You received this message because you are subscribed to the Google Groups "MedicalConspiracies" group.
To unsubscribe from this group and stop receiving emails from it, send an email to medicalconspiracies+unsubscribe@googlegroups.com.
For more options, visit https://groups.google.com/d/optout.

MedicalConspiracies- Cure Copd 2

http://www.naturalnews.com/044664_cannabis_oil_COPD_marijuana.html

--
--
To subscribe: MedicalConspiracies-subscribe@googlegroups.com
Alternative Medicine info: http://www.elementsofhealth.webs.com/

"ClayAdvantage" The Gift of Health http://ClayAdvantage.com/
Holistic Store: http://www.holisticenergystore.com/

Information here in is for educational purpose only; it may be news related,
speculation or opinion. Consult with a qualified MD before deciding on any course of treatment, especially for serious or life-threatening illnesses.
FDA and FTC have not evaluated or endorsed any message or product from this group. http://www.law.cornell.edu/uscode/17/107.shtml

---
You received this message because you are subscribed to the Google Groups "MedicalConspiracies" group.
To unsubscribe from this group and stop receiving emails from it, send an email to medicalconspiracies+unsubscribe@googlegroups.com.
For more options, visit https://groups.google.com/d/optout.

MedicalConspiracies- Go swimming and drown the next day on dry land

https://www.livescience.com/59444-dry-drowning.html?utm_source=notification

--
--
To subscribe: MedicalConspiracies-subscribe@googlegroups.com
Alternative Medicine info: http://www.elementsofhealth.webs.com/

"ClayAdvantage" The Gift of Health http://ClayAdvantage.com/
Holistic Store: http://www.holisticenergystore.com/

Information here in is for educational purpose only; it may be news related,
speculation or opinion. Consult with a qualified MD before deciding on any course of treatment, especially for serious or life-threatening illnesses.
FDA and FTC have not evaluated or endorsed any message or product from this group. http://www.law.cornell.edu/uscode/17/107.shtml

---
You received this message because you are subscribed to the Google Groups "MedicalConspiracies" group.
To unsubscribe from this group and stop receiving emails from it, send an email to medicalconspiracies+unsubscribe@googlegroups.com.
For more options, visit https://groups.google.com/d/optout.

Tuesday, June 6, 2017

MedicalConspiracies- Chikungunya virus in mosquito's, Black Flies, Ticks, Fleas, etc

Diseases transmitted by insects and ticks - CMETE

The Chrysops (horse flies) are the vector for loa loa filariasis. ... about in the ecology of the vectors (dengue fever, chikungunya virus, Lyme disease, etc.). ... America (from Southeastern USA to northern Argentina), and in sub-Saharan Africa.

Chikungunya has sickened more than 10000 in Puerto ... - USA Today

Dec 4, 2014 - It's an unfamiliar tropical virus with an exotic name that causes painful symptoms and has no known treatment or vaccine. It's spreading in the ...

Chikungunya coming to the US? What you need to know about the ...

Jun 17, 2014 - The chikungunya virus, a mosquito-borne illness that causes high fevers and sometimes intense pain, is spreading rapidly throughout the Caribbean. ... Given chikungunya's inevitable crossover to America, here's what you need to know about the virus – and how you can protect ...

WHO | Vector-borne diseases

Black flies. Onchocerciasis (river blindness) ... Some diseases, such as dengue, chikungunya and West Nile virus, are emerging in countries where they were ...

Chikungunya in the Caribbean - Watch - Level 1, Practice Usual ...

Chikungunya is an illness caused by a virus that spreads through mosquito bites. The most common symptoms of chikungunya are fever and joint pain.
Missing: black

Chikungunya in South America - Watch - Level 1, Practice Usual ...

In December 2013, French Guiana reported locally transmitted cases for the first time in South America. Local transmission means that mosquitoes in the area ...
Missing: black

Thousands return from Caribbean with Chikungunya virus | Daily Mail ...

Feb 6, 2015 - An unprecedented outbreak of the Chikungunya virus continues to ... of the U.S. Local mosquitoes that bite a traveler infected with the virus can ...

Black Fly (Simulium) - Valent BioSciences

In the U.S., black fly populations can grow to such numbers that outdoor activities in the affected area become more or less intolerable. The effects range from a ...

[PDF]US EPA - Joint Statement on Insect Repellents by EPA and CDC

Jul 17, 2014 - ticks, fleas, black flies, sand flies, horse flies, stable flies, kissing bugs, lice and ... such as West Nile and chikungunya viruses in the Western.

Chikungunya - San Gabriel Valley Mosquito and Vector Control District

Chikungunya, prevention, transmission, symptoms, prevention, resources, distribution, virus, vector born disease, transmitted.

MedicalConspiracies- Asthma: omalizumab, mepolizumab similarly effective as add-on therapy

https://www.univadis.com/viewarticle/asthma-omalizumab-mepolizumab-similarly-effective-as-add-on-therapy-515843?u=g7Nnk16ewgsgIWoJnBXq6JSx6z6v5u0CKz9KU%2FGYGZX5hk0%2FDCAXtzWSZIhxp3e%2F&utm_source=newsletter%20email&utm_medium=email&utm_campaign=ct-newsletter_wf-automated_fq-daily_cp-medicalupdates_201704&utm_content=1393113&utm_term=automated_daily

Asthma: omalizumab, mepolizumab similarly effective as add-on therapy

Takeaway
  • Omalizumab (Xolair) and mepolizumab (Nucala) showed similar efficacy in patients with asthma that was not well controlled on inhaled corticosteroids (ICS) with or without other agents.

Why this matters

  • To date, there has been no direct comparison study to assess the efficacy of omalizumab and mepolizumab as add-on therapy in patients with asthma. 
  • This is the first meta-analysis to compare the 2 agents in patients with asthma. 
  • Based on available evidence, neither drug can be recommended over the other in patients who qualify for both.

Study design

  • Network meta-analysis of 18 studies (4854 patients) evaluating omalizumab and 4 studies (1620 patients) evaluating mepolizumab since inception till February 2016 met the eligibility criteria.
  • Funding: None disclosed.

Key results

  • Mean difference (MD) in FEV improvement between omalizumab and mepolizumab was 9.3 mL (P=1).
  • Improvement in morning Peak Expiratory Flow Rate and Asthma Control Questionnaire score was similar in both groups (MD, 6.24 L/min [P=.72] and MD, −0.02 [P=1], respectively).

Limitations

  • Heterogeneity between studies.
Coauthored with Deepa Koli, M.Pharmacy

Nachef Z, Krishnan A, Mashtare T, Zhuang T, Mador MJ. Omalizumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis. J Asthma. 2017 May 1 [Epub ahead of print]. doi: 10.1080/02770903.2017.1306548. PMID: 28459601


MedicalConspiracies- Chikungunya: children at higher risk for vertical transmission, significant nervous system morbidity

https://www.univadis.com/viewarticle/chikungunya-children-at-higher-risk-for-vertical-transmission-significant-nervous-system-morbidity-515925?u=g7Nnk16ewgsgIWoJnBXq6JSx6z6v5u0CKz9KU%2FGYGZX5hk0%2FDCAXtzWSZIhxp3e%2F&utm_source=newsletter%20email&utm_medium=email&utm_campaign=ct-newsletter_wf-automated_fq-daily_cp-medicalupdates_201704&utm_content=1393113&utm_term=automated_daily


Chikungunya: children at higher risk for vertical transmission, significant nervous system morbidity

Takeaway

  • As chikungunya virus (CHIKV) infections continue to spread globally (including in North America/the United States), epidemiologic/clinical surveillance is key to predicting outbreaks.
  • This is particularly important for vulnerable children aged 0-12 mo, whose clinical presentation is vastly different than for adults.

Why this matters

  • CHIKV has been linked to significant nervous symptom morbidity, including meningoencephalitis, seizures, Guillain-Barre, myelopathy, and/or myeloneuropathy, especially in small children <12 mo.
  • In very young infants (<3 mo), poorly tolerated fever is prognostic for CHIKV.
  • Clinicians should familiarize themselves with risk for vertical transmission, atypical complications found in pediatric CHIKV, and differences vs adult cases to optimize management/outcomes.

Study design

  • 235 children with CHIKV were evaluated.
  • 128 children were identified by reverse transcription-polymerase chain reaction, and 107 by epidemiologic criteria.
  • Funding: None.

Key results

  • 52% patients were aged 1-12 mo.
  • 53 patients presented with severe complications; most common were seizures, meningoencephalitis, and acute hepatitis.
  • All patients with meningoencephalitis were aged 1-12 mo; the most common clinical manifestations were fever (100%), rash (100%), irritability (100%), and hyperalgesia (93%).
  • Neurological assessment showed mild-moderate brain edema in 7 patients and elevated levels of leukocytes and protein in all 14 patients.
  • 8 patients had vertical transmission Chikungunya virus.

Limitations

  • Retrospective study.

 

Coauthored with Chitra Ravi, MPharm

Samra JA, Hagood NL, Summer A, Medina MT, Holden KR. Clinical Features and Neurologic Complications of Children Hospitalized With Chikungunya Virus in Honduras. J Child Neurol. 2017 Jan 1 [Epub ahead of print]:883073817701879. doi: 10.1177/0883073817701879. PMID: 28459170